Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review

Deepmala,, Slattery, John, Kumar, Nihit, Delhey, Leanna, Berk, Michael, Dean, Olivia, Spielholz, Charles and Frye, Richard 2015, Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review, Neuroscience and Biobehavioral Reviews, vol. 55, pp. 294-321, doi: 10.1016/j.neubiorev.2015.04.015.

Attached Files
Name Description MIMEType Size Downloads

Title Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Author(s) Deepmala,
Slattery, John
Kumar, Nihit
Delhey, Leanna
Berk, MichaelORCID iD for Berk, Michael
Dean, OliviaORCID iD for Dean, Olivia
Spielholz, Charles
Frye, Richard
Journal name Neuroscience and Biobehavioral Reviews
Volume number 55
Start page 294
End page 321
Total pages 28
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015-08
ISSN 1873-7528
Keyword(s) N-acetylcysteine
mechanism of action
Summary N-acetylcysteine (NAC) is recognized for its role in acetaminophen overdose and as a mucolytic. Over the past decade, there has been growing evidence for the use of NAC in treating psychiatric and neurological disorders, considering its role in attenuating pathophysiological processes associated with these disorders, including oxidative stress, apoptosis, mitochondrial dysfunction, neuroinflammation and glutamate and dopamine dysregulation. In this systematic review we find favorable evidence for the use of NAC in several psychiatric and neurological disorders, particularly autism, Alzheimer's disease, cocaine and cannabis addiction, bipolar disorder, depression, trichotillomania, nail biting, skin picking, obsessive-compulsive disorder, schizophrenia, drug-induced neuropathy and progressive myoclonic epilepsy. Disorders such as anxiety, attention deficit hyperactivity disorder and mild traumatic brain injury have preliminary evidence and require larger confirmatory studies while current evidence does not support the use of NAC in gambling, methamphetamine and nicotine addictions and amyotrophic lateral sclerosis. Overall, NAC treatment appears to be safe and tolerable. Further well designed, larger controlled trials are needed for specific psychiatric and neurological disorders where the evidence is favorable.
Language eng
DOI 10.1016/j.neubiorev.2015.04.015
Field of Research 110319 Psychiatry (incl Psychotherapy)
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Elsevier
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 137 times in TR Web of Science
Scopus Citation Count Cited 156 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 466 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Thu, 14 May 2015, 09:55:51 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact